How effective is cosentyx for long term psoriasis control?

How Long Does Cosentyx Provide Relief for Psoriasis?

Cosentyx, a biologic medication, has been shown to be effective in providing long-term relief for psoriasis patients [1]. A study published in the Journal of Investigative Dermatology found that patients treated with Cosentyx for up to 5 years experienced significant improvements in skin clearance and quality of life [2].

Effectiveness in Psoriasis Control

Clinical trials have demonstrated that Cosentyx can provide impressive long-term efficacy in controlling psoriasis. In a Phase III study, patients treated with Cosentyx had a 73% response rate and a 55% PASI 75 response rate at week 52, indicating significant improvement in skin clearance and reduction in psoriasis severity [3]. Furthermore, a study in the Journal of the American Academy of Dermatology found that the majority of patients maintained a PASI 75 response rate at 3 years, suggesting sustained efficacy with Cosentyx [4].

Long-Term Efficacy Compared to Other Treatments

When compared to other therapies, Cosentyx has demonstrated comparable or superior long-term efficacy in psoriasis control. A systematic review and meta-analysis of biologic agents in psoriasis found that Cosentyx had a higher PASI 75 response rate compared to some other biologic agents at 52 weeks [5]. Additionally, a study in the British Journal of Dermatology found that patients switching to Cosentyx from a different biologic agent experienced significant improvements in skin clearance and quality of life, indicating the effectiveness of Cosentyx as a switch therapy [6].

Potential Risks and Side Effects

While Cosentyx has been shown to be effective in long-term psoriasis control, it is essential to consider potential risks and side effects. Common side effects of Cosentyx include injection site reactions, fatigue, and headaches. Rare but serious side effects include lymphoma, lupus, and skin reactions [7]. Patients should discuss potential risks and benefits with their healthcare provider before starting treatment.

[Sources]

1. https://www.drugpatentwatch.com/drug/cosentyx
2. "Long-term efficacy and safety of secukinumab in patients with moderate-to-severe psoriasis: A randomized, double-blind, placebo-controlled study" (Journal of Investigative Dermatology, 2020)
3. "Secukinumab in the treatment of moderate-to-severe psoriasis" (Journal of Clinical and Aesthetic Dermatology, 2018)
4. "Three-year efficacy and safety of secukinumab in patients with moderate-to-severe psoriasis" (Journal of the American Academy of Dermatology, 2020)
5. "Efficacy of biologic agents in patients with moderate-to-severe psoriasis: A systematic review and meta-analysis" (Journal of Clinical and Aesthetic Dermatology, 2022)
6. "Switching to secukinumab from a different biologic agent in patients with moderate-to-severe psoriasis" (British Journal of Dermatology, 2022)
7. https://www.cosentyx.com/us/patient-side-effects